Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vanda Pharmaceuticals Inc VNDA

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.


NDAQ:VNDA - Post by User

User Avatar Image
(10)
•••
  • MikeTesterX
Post by MikeTesteron Aug 03, 2024 10:01am
75 Views
Post# 36162925

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): A Diversified Biop

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA): A Diversified Biophttps://beyondspx.com/2024/08/02/vanda-pharmaceuticals-inc-nasdaqvnda-a-diversified-biopharma-poised-for-growth/
<< Previous
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities